Literature DB >> 22981341

Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes.

Carolina Vizcaíno1, Sylvia Mansilla, Luz-Elena Núñez, Carmen Méndez, José A Salas, Francisco Morís, José Portugal.   

Abstract

The effects of mithramycin SK (MSK) and demycarosyl-3D-β-D-digitoxosyl-mithramycin SK (DIG-MSK; EC-8042), two novel analogs of the antitumor antibiotic mithramycin A, on gene transcription were examined in human HCT116 colon carcinoma cells by quantitative real-time PCR of 89 genes mainly involved in cell cycle control. Each one of the analogs down-regulated a different set of genes, while only five genes were down-regulated by both compounds. Moreover, other genes were significantly up-regulated, among them p21(WAF1)/CDKN1A which is involved in halting cells at the G1 and G2/M checkpoints. These results are rationalized in terms of MSK or DIG-MSK competition with various transcription factors for binding to consensus C/G-rich tracts encompassed in gene promoters. Changes in cell cycle distribution and protein levels after treatment with every analog were consistent with changes observed in gene expression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981341     DOI: 10.1016/j.bcp.2012.08.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.

Authors:  Dinesh K Singh; Rahul K Kollipara; Vamsidara Vemireddy; Xiao-Li Yang; Yuxiao Sun; Nanda Regmi; Stefan Klingler; Kimmo J Hatanpaa; Jack Raisanen; Steve K Cho; Shyam Sirasanagandla; Suraj Nannepaga; Sara Piccirillo; Tomoyuki Mashimo; Shan Wang; Caroline G Humphries; Bruce Mickey; Elizabeth A Maher; Hongwu Zheng; Ryung S Kim; Ralf Kittler; Robert M Bachoo
Journal:  Cell Rep       Date:  2017-01-24       Impact factor: 9.423

2.  Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.

Authors:  Carolina Vizcaíno; Luz-Elena Núñez; Francisco Morís; José Portugal
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

3.  Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Authors:  Atanasio Pandiella; Francisco Morís; Alberto Ocaña; Luz-Elena Núñez; Juan C Montero
Journal:  Oncotarget       Date:  2015-10-20

Review 4.  Understanding the Role of the Transcription Factor Sp1 in Ovarian Cancer: from Theory to Practice.

Authors:  Balachandar Vellingiri; Mahalaxmi Iyer; Mohana Devi Subramaniam; Kaavya Jayaramayya; Zothan Siama; Bupesh Giridharan; Arul Narayanasamy; Ahmed Abdal Dayem; Ssang-Goo Cho
Journal:  Int J Mol Sci       Date:  2020-02-09       Impact factor: 5.923

Review 5.  Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.

Authors:  David Schweer; J Robert McCorkle; Jurgen Rohr; Oleg V Tsodikov; Frederick Ueland; Jill Kolesar
Journal:  Biomedicines       Date:  2021-01-12

Review 6.  SETDB1 in cancer: overexpression and its therapeutic implications.

Authors:  Vanessa J Lazaro-Camp; Kiarash Salari; Xiangbing Meng; Shujie Yang
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.